KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.

doi:10.1186/s13045-026-01817-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.

Journal of hematology & oncology - 2 Jul 2026

Chowdhury Saikat, Ito Ichiaki, Pattalachinti Vinay K, Yousef Abdelrahman M G, Yousef Mahmoud M G, El Khoury Sacha, Hornstein Nicholas, Seldomridge Ashlee Nichole, Hong David, Overman Micheal J, Taggart Melissa W, Foo Wai Chin, Helmink Beth, Fournier Keith F, Shen John Paul

Abstract excerpt

BACKGROUND: Appendiceal adenocarcinoma (AA) is a rare cancer with limited treatment options. KRAS is the most commonly mutated gene in AA and a promising therapeutic target, but its preclinical and translational relevance in AA remains unclear. METHODS: We evaluated KRASG12D-specific (MRTX1133) and pan-KRAS inhibitor (RMC-6236) in KRASmut organoid and PDX models of AA. Tumor-intrinsic and microenvironmental...

Read the complete abstract on PubMed

Topics

Humans
Proto-Oncogene Proteins p21(ras)
Adenocarcinoma
Appendiceal Neoplasms
Animals

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Mice

Male

Antineoplastic Agents

Tumor Microenvironment

Mutation

Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 42393724
DOI: 10.1186/s13045-026-01817-3
PMCID: PMC13536544

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.PMID 42393724Read ↗

KRAS inhibition is an effective therapy for appendiceal adenocarcinomaSemantic proximity Read ↗

Uncovering molecular pathways in appendiceal cancer: A comprehensive characterization for precision oncology.Semantic proximity Read ↗

State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.Semantic proximity Read ↗

An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRCSemantic proximity Read ↗

Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancerSemantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Semantic proximity Read ↗

Next batter up! Targeting cancers with KRAS-G12D mutations.Semantic proximity Read ↗

Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.Semantic proximity Read ↗

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.